Is Immix Biopharma Stock a Good Investment?
Immix Biopharma Investment Advice | IMMX |
- Examine Immix Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Immix Biopharma's leadership team and their track record. Good management can help Immix Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Immix Biopharma's business and its evolving consumer preferences.
- Compare Immix Biopharma's performance and market position to its competitors. Analyze how Immix Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Immix Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Immix Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Immix Biopharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Immix Biopharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Immix Biopharma Stock
Researching Immix Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 40.0% of the company shares are held by company insiders. The book value of Immix Biopharma was currently reported as 0.82. The company recorded a loss per share of 0.84. Immix Biopharma had not issued any dividends in recent years.
To determine if Immix Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immix Biopharma's research are outlined below:
| Immix Biopharma generated a negative expected return over the last 90 days | |
| Immix Biopharma has high historical volatility and very poor performance | |
| Immix Biopharma may become a speculative penny stock | |
| Immix Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (15.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immix Biopharma currently holds about 18.4 M in cash with (11.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32. | |
| Immix Biopharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 40.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Immix Biopharma Posts Quarterly Earnings Results, Misses Expectations By 0.08 EPS |
Immix Biopharma Quarterly Accounts Payable |
|
Immix Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immix Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immix Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 25th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 25th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Immix Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Immix Biopharma's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-12 | 2023-03-31 | -0.14 | -0.18 | -0.04 | 28 | ||
2023-03-27 | 2022-12-31 | -0.22 | -0.27 | -0.05 | 22 | ||
2024-08-11 | 2024-06-30 | -0.21 | -0.15 | 0.06 | 28 | ||
2023-08-11 | 2023-06-30 | -0.17 | -0.24 | -0.07 | 41 | ||
2024-11-09 | 2024-09-30 | -0.16 | -0.24 | -0.08 | 50 |
Know Immix Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immix Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immix Biopharma backward and forwards among themselves. Immix Biopharma's institutional investor refers to the entity that pools money to purchase Immix Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Invst Llc | 2024-06-30 | 27 K | Millennium Management Llc | 2024-06-30 | 26.3 K | Commonwealth Equity Services Inc | 2024-06-30 | 26.1 K | Tritonpoint Wealth Llc | 2024-09-30 | 24.5 K | Squarepoint Ops Llc | 2024-06-30 | 23 K | Corsair Capital Management Llc | 2024-06-30 | 14.2 K | Blackrock Inc | 2024-06-30 | 13.5 K | The Colony Group Llc | 2024-06-30 | 11.9 K | Old National Bancorp | 2024-09-30 | 10 K | Aigh Capital Management, Llc | 2024-09-30 | 1.1 M | Bleichroeder Lp | 2024-09-30 | 850 K |
Immix Biopharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 49.24 M.Market Cap |
|
Immix Biopharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.77) | (0.81) | |
| Return On Capital Employed | (1.00) | (0.95) | |
| Return On Assets | (0.77) | (0.81) | |
| Return On Equity | (0.94) | (0.99) |
Determining Immix Biopharma's profitability involves analyzing its financial statements and using various financial metrics to determine if Immix Biopharma is a good buy. For example, gross profit margin measures Immix Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immix Biopharma's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Immix Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immix Biopharma. Check Immix Biopharma's Beneish M Score to see the likelihood of Immix Biopharma's management manipulating its earnings.
Evaluate Immix Biopharma's management efficiency
Immix Biopharma has return on total asset (ROA) of (0.5685) % which means that it has lost $0.5685 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0381) %, meaning that it created substantial loss on money invested by shareholders. Immix Biopharma's management efficiency ratios could be used to measure how well Immix Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.81 in 2024. Return On Capital Employed is likely to rise to -0.95 in 2024. At this time, Immix Biopharma's Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 144.3 K in 2024, whereas Total Assets are likely to drop slightly above 12 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.93 | 0.98 | |
| Tangible Book Value Per Share | 0.93 | 0.98 | |
| Enterprise Value Over EBITDA | (6.35) | (6.67) | |
| Price Book Value Ratio | 7.31 | 7.68 | |
| Enterprise Value Multiple | (6.35) | (6.67) | |
| Price Fair Value | 7.31 | 7.68 | |
| Enterprise Value | 19.4 M | 28.8 M |
Immix Biopharma has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 0.104 |
Basic technical analysis of Immix Stock
As of the 26th of November, Immix Biopharma retains the Risk Adjusted Performance of (0.02), standard deviation of 5.53, and Market Risk Adjusted Performance of (0.13). Immix Biopharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Immix Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immix Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immix Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immix Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immix Biopharma's Outstanding Corporate Bonds
Immix Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immix Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immix bonds can be classified according to their maturity, which is the date when Immix Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Understand Immix Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Immix Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.13) | |||
| Mean Deviation | 3.87 | |||
| Coefficient Of Variation | (3,182) | |||
| Standard Deviation | 5.53 | |||
| Variance | 30.55 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (1.05) | |||
| Treynor Ratio | (0.14) | |||
| Maximum Drawdown | 32.68 | |||
| Value At Risk | (8.22) | |||
| Potential Upside | 7.06 | |||
| Skewness | 1.25 | |||
| Kurtosis | 3.86 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.13) | |||
| Mean Deviation | 3.87 | |||
| Coefficient Of Variation | (3,182) | |||
| Standard Deviation | 5.53 | |||
| Variance | 30.55 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.35) | |||
| Total Risk Alpha | (1.05) | |||
| Treynor Ratio | (0.14) | |||
| Maximum Drawdown | 32.68 | |||
| Value At Risk | (8.22) | |||
| Potential Upside | 7.06 | |||
| Skewness | 1.25 | |||
| Kurtosis | 3.86 |
Consider Immix Biopharma's intraday indicators
Immix Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immix Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 25794.38 | |||
| Daily Balance Of Power | (0.39) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 1.8 | |||
| Day Typical Price | 1.77 | |||
| Price Action Indicator | (0.11) | |||
| Period Momentum Indicator | (0.07) |
Immix Stock media impact
Far too much social signal, news, headlines, and media speculation about Immix Biopharma that are available to investors today. That information is available publicly through Immix media outlets and privately through word of mouth or via Immix internal channels. However, regardless of the origin, that massive amount of Immix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immix Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immix Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immix Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immix Biopharma alpha.
Immix Biopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Immix Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Immix Biopharma Corporate Management
| JD MBA | CoFounder | Profile | |
| David Marks | Chief Therapy | Profile | |
| Gabriel BA | CFO Director | Profile | |
| Gerhard Bauer | Head Manufacturing | Profile | |
| MD FFPM | Chief Development | Profile | |
| Nandan BS | Manufacturing Chemistry | Profile | |
| MBA MD | Chairman CoFounder | Profile |
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.